SCRIBE Trademark

Trademark Overview

On Friday, November 9, 2018, a trademark application was filed for SCRIBE with the United States Patent and Trademark Office. The USPTO has given the SCRIBE trademark a serial number of 88188800. The federal status of this trademark filing is REGISTERED as of Tuesday, June 28, 2022. This trademark is owned by Scribe Therapeutics Inc.. The SCRIBE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering
scribe

General Information

Serial Number88188800
Word MarkSCRIBE
Filing DateFriday, November 9, 2018
Status700 - REGISTERED
Status DateTuesday, June 28, 2022
Registration Number6775193
Registration DateTuesday, June 28, 2022
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 26, 2019

Trademark Statements

Goods and ServicesScientific and medical research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering research and development of pharmaceuticals, biological preparations and therapeutic products and services; design and development of engineered cells for use in scientific research and drug discovery and development; Providing medical research and scientific research information in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic diseases, gene therapy and cell therapy, and genetic engineering

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 28, 2018
Primary Code042
First Use Anywhere DateThursday, October 1, 2020
First Use In Commerce DateThursday, October 1, 2020

Trademark Owner History

Party NameScribe Therapeutics Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501
Party NameScribe Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressAlameda, CA 94501
Party NameScribe Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBerkeley, CA 94705

Trademark Events

Event DateEvent Description
Tuesday, June 28, 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, June 28, 2022REGISTERED-PRINCIPAL REGISTER
Friday, May 27, 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, May 26, 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, May 25, 2022STATEMENT OF USE PROCESSING COMPLETE
Friday, May 20, 2022USE AMENDMENT FILED
Friday, May 20, 2022TEAS STATEMENT OF USE RECEIVED
Tuesday, November 30, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 29, 2021SOU EXTENSION 5 GRANTED
Tuesday, November 16, 2021SOU EXTENSION 5 FILED
Tuesday, November 16, 2021TEAS EXTENSION RECEIVED
Wednesday, May 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 17, 2021SOU EXTENSION 4 GRANTED
Monday, May 17, 2021SOU EXTENSION 4 FILED
Monday, May 17, 2021TEAS EXTENSION RECEIVED
Wednesday, November 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 9, 2020SOU EXTENSION 3 GRANTED
Monday, November 9, 2020SOU EXTENSION 3 FILED
Monday, November 9, 2020TEAS EXTENSION RECEIVED
Tuesday, April 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 17, 2020SOU EXTENSION 2 GRANTED
Friday, April 17, 2020SOU EXTENSION 2 FILED
Friday, April 17, 2020TEAS EXTENSION RECEIVED
Thursday, March 26, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 25, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, March 3, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 3, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 3, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, March 3, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 3, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 3, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, October 22, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 18, 2019SOU EXTENSION 1 GRANTED
Friday, October 18, 2019SOU EXTENSION 1 FILED
Friday, October 18, 2019TEAS EXTENSION RECEIVED
Thursday, September 19, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, September 19, 2019ASSIGNED TO LIE
Monday, September 16, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, May 21, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 26, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 26, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 6, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, February 14, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 13, 2019ASSIGNED TO EXAMINER
Wednesday, November 28, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, November 13, 2018NEW APPLICATION ENTERED

Related Keywords

scribe gene research modulation transcriptional therapy genetic engineering editing genome development